Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 11, 2025
PDS Biotech Leadership to Participate in March Conferences
GlobeNewswire
·
March 11, 2025
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
·
March 11, 2025
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancer CRB 913 SAD/MAD obesity study expected to start in March 2025 $149m of cash …
iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025
GlobeNewswire
·
March 11, 2025
NASHUA, N.H., March 11, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, …
Abacus Life Announces Rebrand to Abacus Global Management, Unveils Expanded Business Lines
GlobeNewswire
·
March 11, 2025
ORLANDO, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- Abacus Life (NASDAQ: ABL), a leader in the alternative asset management space, today announced it has rebranded to Abacus Global Management (abacusgm.com), effective immediately. The new name better …
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
GlobeNewswire
·
March 11, 2025
MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's …
Aventon announces the All-New Abound LR ﹣ The Next Generation Cargo eBike
GlobeNewswire
·
March 11, 2025
Brea, CA, March 11, 2025 (GLOBE NEWSWIRE) -- Brea, CA – March 11, 2025 – Aventon, an industry leader in electric bicycles, is excited to introduce the all-new Abound LR(Long Rack) to the Abound family. With the popularity and success from the original …
Advancial Gives $30,865.97 Donation to Children’s HealthSM
GlobeNewswire
·
March 11, 2025
Plano, TX, March 11, 2025 (GLOBE NEWSWIRE) -- On Tuesday, February 18 Advancial Federal Credit Union presented Children’s Health, one of the largest and most prestigious health care institutions in the country and the leading pediatric health care system …
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
GlobeNewswire
·
March 11, 2025
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage …
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
GlobeNewswire
·
March 11, 2025
Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for …
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
GlobeNewswire
·
March 11, 2025
- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation …
AmMax Bio Announces Presentation at BIO-Europe Spring 2025
GlobeNewswire
·
March 11, 2025
REDWOOD CITY, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that Laura Zhu, Ph.D., MBA, the Company’s Chief Business …
PharmaTher Receives US FDA Approval Goal Date for Ketamine
GlobeNewswire
·
March 11, 2025
TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the commercialization of Ketamine, is pleased to announce today that the …
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
GlobeNewswire
·
March 11, 2025
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye …
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
GlobeNewswire
·
March 11, 2025
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive …
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
GlobeNewswire
·
March 11, 2025
Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE …
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
GlobeNewswire
·
March 11, 2025
ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), …
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 11, 2025
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic Topline …
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 11, 2025
Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for …
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH
GlobeNewswire
·
March 11, 2025
Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N …
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
GlobeNewswire
·
March 11, 2025
WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that …